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S U M M A R Y
Objective: The aim of this study was to evaluate the expression of nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) in the cerebrospinal ﬂuid (CSF) of children with Epstein–Barr virus
(EBV)-induced meningoencephalitis (ME) in order to establish a possible correlation with laboratory
ﬁndings and neurological manifestations.
Methods: A prospective observational clinical study was performed on 10 children with viral ME, ﬁve of
them with EBV-induced ME. As controls, we used CSF samples collected from children admitted with
febrile seizures. Neurotrophin levels were measured using an enzyme immunoassay.
Results: Signiﬁcantly higher levels of BDNF and NGF were detected in all patients with viral ME
compared to controls. Moreover, in patients with EBV-induced ME, the neurotrophin levels were higher
than in those with other viral ME. Of note, in children with EBV-induced ME, we found a signiﬁcant
correlation between neurotrophic factor levels and the number of lymphocytes in the CSF (p < 0.001). In
these patients we also found a signiﬁcant correlation between BDNF expression and the blood platelet
count (p < 0.001). Interestingly, two patients with EBV-induced ME showed a correlation between
neurotrophin increase and persistent brain abnormalities, such as prolonged alteration of mental status,
psychomotor agitation, and athetosis.
Conclusions: Viral ME induces an early and strong increased biosynthesis of neurotrophic factors. This
neurotrophin over-expression is likely to play a key role in the mechanisms of neuronal inﬂammation
and in the severity of brain damage, particularly in EBV-induced ME.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Epstein–Barr virus (EBV) is a member of the herpes virus family
and affects B-cells and epithelial lines, leading to a variety of
manifestations, ranging from subclinical infections to infectious
mononucleosis, neoplasms, and severe meningoencephalitis (ME).
EBV infection may also result in other neurological complications,
such as cerebellitis, Guillain–Barre´ syndrome, seizures, and
psychiatric disorders, occurring in about 6–7% of hospitalized
patients.1,2 Children with EBV-induced ME may also show       
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in which they have perceptual distortions of personal body image,
size, and spatial relationships.3 Movement disorders indicative of
extrapyramidal involvement, such as athetosis, Parkinson-like
syndrome, and Sydenham-type chorea, have also been reported,
while acute psychosis and transient global amnesia may be the
only neurological manifestations in some cases of EBV-induced ME
in children.4–6
Several hypotheses to explain this particular neurological
virulence of EBV infection in children have been advocated,
including down-regulation of type 1 interferon expression,
apoptosis, and hyperinduction of proinﬂammatory cytokines.7,8
It has also been reported that neurotrophin up-regulation plays a
key role in the inﬂammatory host response after EBV-induced
ME.9,10 The neurotrophin family includes nerve growth factor
(NGF) and other structurally related neuropeptides, such as brain-
derived neurotrophic factor (BDNF) and neurotrophins 3/4. NGF isociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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cerebral cortex. It acts on forebrain cholinergic neurons located in
the septum, the nucleus of the diagonal band of Broca, and the
nucleus basalis of Meynert.11,12 The forebrain cholinergic neurons,
which provide the majority of cholinergic innervation to the
cerebrum and hippocampus, are particularly vulnerable in EBV-
induced ME, and this may account for much of the associated
memory and cognitive function impairment. BDNF is a protein
consisting of 119 amino acids, produced (along with its receptor
TrkB) in the hippocampus, amygdala, thalamus, and cerebellum; it
exerts its biological effects on the survival and function of selected
populations of dopaminergic, serotoninergic, and GABAergic
neurons.13 When neurotrophins bind to their high afﬁnity
receptors, intracellular signal channels, including mitogen-acti-
vated protein kinase (MAPK), phosphoinositide 3 (PI3) kinase, and
phospholipase C-g (PLC-g) channels, are activated to allow
manifestation of the various neurotrophin functions.14 As it is
known that NGF and BDNF are expressed locally in the
hippocampus and hypothalamus of the mature brain, these
neurotrophins are considered to be related to higher brain
functions, such as perception, learning, and memory, exerting a
key role in the formation, development, and maintenance of
neuronal networks in the brain.
According to the mechanisms elicited by these neurotrophins
on brain function, the objective of the present study was to
investigate the expression of NGF and BDNF in the cerebrospinal
ﬂuid (CSF) of children with EBV-induced ME and to determine
whether a correlation with laboratory ﬁndings and neurological
manifestations exists in these patients.
2. Patients and methods
We conducted a prospective observational clinical study among
children with a diagnosis of viral ME admitted to the Pediatric
Infectious Disease Unit (PIDU) of our department in Rome, Italy,
from January 2010 to February 2013. Children were grouped
according to age, etiology of viral ME, ﬁndings on cerebral
magnetic resonance imaging (MRI), clinical and laboratory
characteristics, and ﬁnal outcome. Ten patients were enrolled in
the study: ﬁve of them had EBV-induced ME and the other ﬁve had
acute viral ME due to other viral infections. As controls, we used
CSF samples collected from children admitted with non-central
nervous system (CNS)-related disorders, such as febrile seizures,
for whom a lumbar puncture had been performed to rule out
infective meningitis. Controls were matched for age and sex,
respectively.
All patients underwent supportive therapy for acute viral ME.
Hyperglycemia and electrolyte and metabolic derangements were
strictly avoided. Fever was treated with antipyretics, such as
paracetamol. Cerebral MRI was performed in all patients after the
diagnosis of acute viral ME. To measure the levels of NGF and BDNF,
we collected samples of CSF by lumbar puncture at admission to
the hospital, before any treatment had been started. The CSF
samples were submitted to microbiological and biochemical
analysis (leukocyte counts, protein and glucose concentrations).
CSF samples (about 1 ml) were centrifuged for 10 min at 5000 rpm
and the supernatant was immediately stored at 70 8C until
analysis. The outcomes of the children were assessed at discharge
from the hospital using the Glasgow outcome score (GOS): a GOS of
1 was assigned to the children who died, a GOS of 2 to those in a
persistent vegetative state, a GOS of 3 to those with severe
neurological deﬁcits, a GOS of 4 for mild neurological deﬁcits, and a
GOS of 5 for completely healthy children.
The study was approved by the institutional review board, and
the parents of participating children were informed regarding the
study and provided written informed consent.2.1. NGF assay
NGF was quantiﬁed using a two-site immunoassay kit from
Promega (USA). In brief, 96-well plates were coated with 100 ml/
well of monoclonal anti-NGF antibody. After overnight incubation
at 4 8C, the antibody was removed from the plates and the samples
were incubated in coated wells (100 ml/well) for 6 h at room
temperature. The plates were then washed 5 times with 0.05 M
carbonate buffer (pH 9.5) and 1% bovine serum albumin (BSA) and
the antigen was incubated overnight with polyclonal anti-human
NGF antibody at 4 8C. The plates were washed again with 0.05 M
carbonate buffer (pH 9.5) and 1% BSA and incubated with anti-
chicken IgY horseradish peroxidase (HRP) conjugate for 2 h at
room temperature. The plates were incubated with a tetramethyl-
benzidine (TMB)/peroxidase substrate solution for 15 min, and 1 M
phosphoric acid was added (100 ml/well). The colorimetric
reaction product was measured at 450 nm. NGF concentrations
were interpolated from an NGF standard curve ranging from 15.6
to 1000 pg/ml of puriﬁed human NGF. The sensitivity of this assay
was 3 pg/ml and cross-reactivity with other related neurotrophins
was less than 5%. All assays were performed in triplicate and the
NGF concentration expressed in pg/ml.
2.2. BDNF assay
The endogenous BDNF was quantiﬁed using a two-site enzyme
immunoassay kit (Promega, USA). As performed for the NGF assay,
96-well immunoplates (Nunc) were coated with 100 ml/well of
monoclonal anti-mouse BDNF antibody and incubated overnight at
4 8C. The plates were then washed three times with wash buffer,
and the samples were incubated, with shaking, in the coated wells
(100 ml each) for 2 h at room temperature. After additional washes,
the antigen was incubated, with shaking, with an anti-human
BDNF antibody for 2 h at room temperature. The plates were
washed again with wash buffer and then incubated with an anti-
IgY human puriﬁed antibody for 1 h at room temperature. After
another washing, the plates were incubated with a TMB/
peroxidase substrate solution for 15 min, and 1 M phosphoric
acid was added to the wells (100 ml/well). The colorimetric
reaction product was measured at 450 nm using an ELISA reader
(Dynatech MR 5000, Germany). BDNF concentrations were
determined from the regression line for the BDNF standard
(ranging from 7.8 to 500 pg/ml puriﬁed mouse BDNF), incubated
under similar conditions in each assay. The sensitivity of the assay
was 15 pg/ml of BDNF, and the cross-reactivity with other related
neurotrophins (i.e., NGF, neurotrophin 3, and neurotrophin 4/5)
was less than 3%. The BDNF concentration was expressed in pg/ml
for liquid samples. All assays were performed in triplicate.
2.3. EBV PCR assay
The EBV genome was extracted from the CSF samples by
automated nucleic acid extraction system NucliSens EasyMAG
(bioMe´rieux SA, Marcy l’Etoile, France) and ampliﬁed using the
commercial real-time PCR kit EBV Q PCR Alert (EliTech Group,
Nanogen Advance Diagnostics, Torino, Italy) and the ABI PRISM 7300
Sequencer Detection System (Applied Biosystems, CA, USA). The EBV
probe, labeled with FAM ﬂuorophor and blocked by the MGB-NFQ
group, is speciﬁc for a region of the gene that codiﬁes the Epstein–
Barr nuclear antigen 1 (EBNA-1) protein of EBV. This product is able
to quantify from 10 to 1 000 000 copies for the DNA of the gene
coding the EBNA-1 protein of EBV per ampliﬁcation reaction.
2.4. Statistical analysis
The statistical analysis of the data was performed using
the StatSoft package (OK, USA), considering the experimental
Table 1
Clinical and demographic characteristics of children with viral meningoencephalitis
Age Sex Clinical manifestations at admission NGF (pg/ml) BDNF (pg/ml) Treatment Outcome
Children with EBV-induced ME
10.3 months M Mental status alterations 70.9 523.44 Supportive therapy Poor
38.4 months F Fever and seizures 60.4 456.32 Supportive therapy Good
5.5 years M Fever and lethargic state 55.7 462.55 Supportive therapy Good
18.6 months F Fever and seizures 55.3 478.80 Supportive therapy Good
19.5 months M Mental status alterations 63.7 505.45 Supportive therapy Poor
Children with non-EBV-induced ME
12.2 months M Fever and seizures 32.6 290.30 Supportive therapy Good
16.5 months M Fever and seizures 24.7 235.55 Supportive therapy Good
4.3 years F Fever and lethargic state 19.8 245.70 Supportive therapy Good
15.4 months M Fever and seizures 37.6 285.10 Supportive therapy Good
31.5 months F Fever and lethargic state 26.9 270.25 Supportive therapy Good
NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; EBV, Epstein–Barr virus; ME, meningoencephalitis; M, male; F, female.
Figure 1. Correlation between the age of patients and controls and (a) NGF, and (b)
BDNF levels in the CSF. We found no signiﬁcant correlation between neurotrophin
levels and age (p > 0.05 for every tested analysis).
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using the Tukey–Kramer test. The non-parametric Mann–Whit-
ney two-tailed, two-sample test was used to perform statistical
comparisons between children with viral ME and the control
group. Because the study population was small, we did not
perform a multivariate analysis to adjust for the effect of each
parameter in the presence of the others. Spearman correlation
coefﬁcients were used to analyze the correlations between NGF
and BDNF levels, results of microbiological and biochemical
analyses, and GOS at discharge. A p-value of <0.05 was considered
signiﬁcant.
3. Results
During the study period, 10 children with acute viral ME (six
boys and four girls) and 10 control patients were admitted to our
institution and were included in the study (Table 1). These children
were aged 10.3 months to 5.6 years, with a mean age of 30.6  39.1
months (median age 19.5 months). Patients with EBV-induced ME
and acute viral ME were matched for age with controls.
We found no signiﬁcant correlation between the age of patients
and controls and the levels of neurotrophins in the CSF (Figure 1).
The etiology of viral ME was represented by enterovirus infection
in three cases and echovirus infection in two, while the other ﬁve
patients had a diagnosis of EBV-induced ME. The diagnosis of viral
ME was conﬁrmed by PCR positivity and also by the presence of
EBV DNA (>500 copies/ml) in the CSF of EBV-induced ME patients.
The control group comprised 10 children with febrile seizures and
with negative lumbar puncture. The control group children were
aged 12.2 months to 4.9 years, with a mean age of 25.5  31.6
months (median age 16.5 months).
All control group children and all non-EBV-induced ME patients
had a GOS of 5 at discharge, while in the group of EBV-induced ME,
three patients had a GOS of 5 and two patients had a GOS of 3. At
admission to the hospital, both of the children with a discharge
GOS of 3 had been disoriented with respect to time and place and
their attention, concentration, and short-term memory were
affected. Serial neuropsychiatric evaluations revealed a disphoric
mood, hallucinations, acute psychosis, dystonic movements, and
retarded psychomotor activity without any physical abnormalities
during the hospitalization. Due to the persistence of these
neurological manifestations, intravenous midazolam (2 g/kg/m
in continuous intravenous infusion) treatment was given for 2
weeks, however there was no signiﬁcant improvement. Brain
edema and non-enhancing periventricular and leptomeningeal
hyperintensities were demonstrated on MRI examination, while an
electroencephalogram (EEG) showed diffuse slowing in both
cerebral hemispheres. Due to persistence of the mental status
alterations, cerebral positron emission tomography (PET) andsingle photon emission computed tomography (SPECT) studies
were performed; results were normal, and haloperidol treatment
was started in both children. At 1 week after the start of
haloperidol treatment, both children improved gradually; however
mental status alteration and psychomotor agitation persisted. Due
to the progressive improvement in their neurological conditions,
both patients were discharged from the hospital at approximately
45 days after admission with a GOS of 3.
3.1. Mean levels of NGF and BDNF in the CSF of control group children
Both neurotrophins were detected in the CSF of children in the
control group, although the levels differed signiﬁcantly. NGF levels
were signiﬁcantly lower (10.7  2.1 pg/ml; p < 0.001) than BDNF
levels (28.2  9.2 pg/ml) (Figure 2a).
Figure 2. Neurotrophin levels (median and range) in the CSF of patients enrolled in
the study. (a) Neurotrophin CSF levels in control group children; (b) NGF, and (c)
BDNF concentrations in the CSF of children with EBV and non-EBV-induced
meningoencephalitis.
Figure 3. Correlations between the number of lymphocytes in the CSF and (a) NGF,
and (b) BDNF levels in children enrolled in the study.
Figure 4. Correlation between blood platelet counts and BDNF levels in the CSF of
the children studied.
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As shown in Figure 2b, mean NGF levels in the CSF were
different in children with EBV-induced ME compared to children
with non-EBV-induced ME (65.2  19.7 pg/ml vs. 28.4  7.7 pg/ml;
p < 0.001). Moreover, in children with EBV-induced ME, a statistically
signiﬁcant association (p < 0.001) was found between mean NGF
levels and the number of lymphocytes in the CSF (Figure 3a). No
signiﬁcant correlations were found between mean NGF levels and CSF
glucose and protein concentrations. Among the patients with EBV-
induced ME, two children with more elevated NGF levels in the CSF
(70.9 pg/ml and 63.7 pg/ml, respectively) showed prolonged
alteration of mental status, hallucinations, acute psychosis, dystonic
movements such as athetosis, retarded psychomotor activity, and
memory deﬁcits.3.3. BDNF expression in patients with acute viral meningoencephalitis
Figure 2c shows the mean BDNF levels in the CSF of patients
with EBV-induced ME compared to children with non-EBV-
induced ME (485  105.5 pg/ml vs. 265  75.8 pg/ml; p < 0.001).
As for NGF, a statistically signiﬁcant correlation (p < 0.001) was found
between mean BDNF levels and the number of lymphocytes in the CSF
of children with EBV-induced ME (Figure 3b). We also detected a
statistically signiﬁcant correlation between BDNF levels in the CSF
and the blood platelet count in patients affected by EBV-induced ME
(p < 0.001) (Figure 4). No correlations were found between mean
BDNF levels and CSF glucose and protein concentrations. We also
found that two children with EBV-induced ME and prolonged
alteration of mental status showed the highest BDNF levels in the
CSF (523.44 pg/ml and 505.45 pg/ml, respectively).
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Our study, despite the limited patient sample evaluated,
provides evidence that both NGF and BDNF levels are increased
in the CSF of children with viral ME compared to controls,
suggesting that these factors play a key role in the molecular
events related to brain inﬂammation. Moreover, we found both of
these neurotrophins to be increased in patients with EBV-induced
ME compared to patients with non-EBV-induced ME and that this
over-expression was signiﬁcantly correlated with disease severity
and increased numbers of lymphocytes in the CSF. Of note, two
children affected by EBV-induced ME, in whom we detected higher
NGF and BDNF levels, showed prolonged alteration of mental
status characterized by psychomotor agitation, hallucinations,
acute psychosis, dystonic movements, and retarded psychomotor
activity. Interestingly, we also found that BDNF levels, but not NGF
levels, were signiﬁcantly associated with an increased blood
platelet count in children with EBV-induced ME.
To date, it has been difﬁcult to fully elucidate the role of
neurotrophins in the mechanisms of the virus–host response
because both proinﬂammatory and neuroprotective effects have
been reported. BDNF is known to have many single nucleotide
polymorphisms (SNPs) in humans, and is attracting attention as a
potential molecular mediator of higher brain functions, such as
environmental perception and learning, and as a mediator of
individual differences in the risk of developing psychiatric and
neurological disorders, such as schizophrenia and Alzheimer’s
disease.15–18
Experimental animal models have shown that elevated
concentrations of BDNF in the brain are responsible for some
modiﬁcations of the host immune response to CNS viral infections,
and that the exposure of EBV-transformed B-lymphocytes to BDNF
triggers the phosphorylation of the high afﬁnity receptor of BDNF,
TrkB.19 Our results are consistent with these ﬁndings because we
found a signiﬁcant correlation between increased numbers of
lymphocytes and higher levels of BDNF in the CSF of children with
EBV-induced ME, suggesting that activated lymphocytes may
determine an increased biosynthesis of this neurotrophin in the
infected brain. Recently, in an experimental animal model of
different brain injuries, lymphocytes, and in particular activated T-
cells, were reported to express BDNF and other neurotrophins; T-
cells were also reported to be a potential source of BDNF and
neurotrophin 3 after nerve damage, providing ‘protective autoim-
munity’ in the repair of the injured nervous system.20,21 Based on
these ﬁndings, we believe that the observed BDNF up-regulation in
the CSF of our patients was secondary to rapid lymphocyte
activation by EBV infection and that this over-expression
represents an important process in the mechanisms of the
inﬂammatory host response after viral infection.
Moreover, our results also demonstrated that in children with
EBV-induced ME, the higher levels of BDNF were signiﬁcantly
associated with the blood platelet count. BDNF is stored and
released by activated platelets/vascular endothelium at the site of
injury to facilitate the repair of peripheral nerve damage or other
tissue containing BDNF receptors, suggesting that the increased
biosynthesis of this neurotrophin is correlated with the severity of
the nervous tissue damage induced by inﬂammation.22–24 A large
amount of BDNF is stored in human platelets and these provide an
important source of BDNF for regenerating peripheral and central
neurons at the site of nerve damage.25 BDNF in human platelets has
biological and molecular activities very similar to those of BDNF in
the brain. Two pools of BDNF have been identiﬁed in platelets: in
a-granules and in cytoplasm. Infections and shear stress induce a
rapid release of BDNF from the a-granules of platelets, which
appear to bind, store, and release BDNF upon activation at the site
of nerve injury.26,27Recently, it has also been reported that platelet BDNF is
signiﬁcantly increased in patients with major depressive disorders
and in children with head injuries, and that the increased
concentration of this neurotrophin is correlated with the severity
of the trauma.28 According to these ﬁndings we hypothesize that
the source of increased BDNF was also from circulating platelets in
response to the viral infection in the children with EBV-induced
ME; however it is not possible at this time to differentiate the two
molecular forms of this neurotrophin in the brain.
Neurotrophic factor biosynthesis has been attributed to
neurons, astrocytes, and microglia, rapidly activated by different
types of brain injury. Lymphocytes have been shown to express
neurotrophin and neurotrophin receptors in experimental animal
models of inﬂammatory and infectious diseases.29 Thus, it is likely
that the rapid activation of lymphocytes due to EBV infection is
responsible for the increased neurotrophin biosynthesis in
children with viral ME, conﬁrming the close correlation between
the immune system and the intracerebral release of BDNF and NGF,
as reported previously in the literature.30–32 Neurotrophin up-
regulation has also been demonstrated in several neurological
manifestations, whereas early over-expression of TrkA/TrkB
receptors has been shown in inﬂammatory and traumatic brain
injury.33 In support of these ﬁndings, experimental and clinical
studies have reported a massive BDNF and NGF release in the
hypothalamus and in forebrain cholinergic areas of the brain in
response to infectious diseases, stress, trauma, and epileptic status,
conﬁrming that the neurotrophin up-regulation is associated with
neurodegenerative and neuropsychiatric-related disorders in the
involved patients.32,34–36 In accordance with these observations,
for our two children with neuropsychiatric disorders, the increased
intracerebral biosynthesis of BDNF and NGF induced by EBV
infection might also be responsible for the prolonged alteration in
mental status, as reported previously in the literature.37–39
In conclusion, our study showed an early and strong BDNF and
NGF over-expression in the CSF of children with viral ME, namely
in patients with EBV-induced ME, in whom we also detected a
signiﬁcant correlation between increased levels of neurotrophins
and the number of lymphocytes. The increased intracerebral
biosynthesis of BDNF and NGF might also be the underlying
molecular cause of the speciﬁc neuropsychiatric-related disorders
observed in two children with EBV-induced ME. Further clinical
and experimental investigations are necessary to identify the
neurotrophin neuronal networks in the damaged brains of patients
with inﬂammatory and infectious diseases. Deﬁning the relation-
ships between intracerebral release of neurotrophins and the
pathophysiology of EBV-induced ME may help to shed light on the
molecular aspects of EBV infections.
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